Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815682 · ClinicalTrials.gov registry record · Phase 1
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
A Phase 1 study, sponsored by Repertoire Immune Medicines.
- Terminated
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
NCT03815682: Clinical Trial Phase 1 study, sponsored by Repertoire Immune Medicines.
NCT03815682 is a Phase 1 study that was terminated before completion, run by Repertoire Immune Medicines. The registered enrollment target is 23 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03815682, a Phase 1 study, was terminated before completion, sponsored by Repertoire Immune Medicines.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
Primary Outcome
Safety of RPTR-147:1 as a monotherapy
Interventions
- BIOLOGICAL Arm A: RPTR-147:1
- BIOLOGICAL Arm B: RPTR-147:1 and Pembrolizumab
- BIOLOGICAL Arm C: RPTR-147:2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2018-10-24 |
| Est. Completion | 2022-10-11 |
| Phase | Phase 1 |
Why NCT03815682 stopped before completion
NCT03815682 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (62% lower).
The record links to 0 conditions, and to 3 interventions - of which Arm A: RPTR-147:1 is the first listed.
NCT03815682 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03815682 about?
NCT03815682 is a clinical study titled "RPTR-147 in Patients With Selected Solid Tumors and Lymphomas". The purpose of this study is to assess the safety and tolerability of escalating doses of RPTR-147 as a monotherapy and in combination with Pembrolizumab in patients with selected solid tumors and lymphomas.
What is the current status of trial NCT03815682?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2018-10-24. Estimated completion is 2022-10-11.
What interventions are being tested in trial NCT03815682?
The interventions under investigation include: Arm A: RPTR-147:1 (BIOLOGICAL), Arm B: RPTR-147:1 and Pembrolizumab (BIOLOGICAL), Arm C: RPTR-147:2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03815682?
This trial is sponsored by Repertoire Immune Medicines, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03815682's enrollment target sits among peer trials
23 1596th of 2000 higher than 400 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI